<PAGE> 1
----------------------------
OMB APPROVAL
----------------------------
OMB Number: 3235-0145
Expires: December 31, 1999
Estimated average burden
hours per response....14.90
----------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 3)*
Cantab Pharmaceuticals plc
- --------------------------------------------------------------------------------
(Name of Issuer)
American Depositary Shares representing
Ordinary Shares, par value (pound).02 per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
138084108
---------------------
(CUSIP Number)
December 31, 1999
- --------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SEC 1745 (2/92)
Page 1 of 8 pages
<PAGE> 2
- -------------------------- -----------------------------
CUSIP NO. 138084108 13G PAGE 2 OF 8 PAGES
--- ---
- -------------------------- -----------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Biotechnology Venture Fund, S.A. (i.l.)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
2,908,327
NUMBER OF ---------------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY -0-
EACH ---------------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON
WITH 2,908,327
---------------------------------------------------------
8 SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,489,999 Ordinary Shares (see Item 4(a) of attached Schedule)
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ]
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.9%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 2 of 8 pages
<PAGE> 3
- -------------------------- -----------------------------
CUSIP NO. 138084108 13G PAGE 3 OF 8 PAGES
--- ---
- -------------------------- -----------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Tetraven Fund S.A. (i.l.)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
581,672
NUMBER OF ---------------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY -0-
EACH ---------------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON
WITH 581,672
---------------------------------------------------------
8 SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,489,999 Ordinary Shares (see Item 4(a) of attached Schedule)
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ]
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.9%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 3 of 8 pages
<PAGE> 4
ITEM 1(a). NAME OF ISSUER: Cantab Pharmaceuticals plc.
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
184 Cambridge Science Park, Milton Road, Cambridge CB4 4GN
United Kingdom.
ITEM 2(a). NAME OF PERSON FILING: Biotechnology Venture Fund, S.A. (i.l.)
("Biotechnology") and Tetraven Fund S.A. (i.l.) ("Tetraven").
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The
address of the principal business office of Biotechnology and
Tetraven is 231 Val des Bons Malades, L-2121 Luxembourg-Kirchberg.
ITEM 2(c). CITIZENSHIP: Each of Biotechnology and Tetraven is a corporation
organized under the laws of Luxembourg.
ITEM 2(d). TITLE OF CLASS OF SECURITIES: American Depositary Shares
representing Ordinary Shares, par value(pound).02 per share
("Ordinary Shares").
ITEM 2(e). CUSIP NUMBER: 138084108.
ITEM 3. If this statement is filed pursuant to Rules 13d-1(b), or
13d-2(b) or (c), check whether the person filing is a:
(a) [ ] Broker or Dealer registered under Section 15 of the
Exchange Act;
(b) [ ] Bank as defined in Section 3(a)(6) of the Exchange Act;
(c) [ ] Insurance Company as defined in Section 3(a)(19) of the
Exchange Act;
(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act;
(e) [ ] An investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance
with Rule 13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance
with Rule 13d-1(b)(1)(ii)(G);
(h) [ ] A savings association as defined in Section 3(b) of the
Federal Deposit Insurance Act;
(i) [ ] A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the Investment
Company Act;
(j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J);
Not applicable. This statement on Schedule 13G is not filed
pursuant to Rule 13d-1(b), Rule 13d-2(b) or Rule 13d-2(c).
ITEM 4. OWNERSHIP.
(a) Amount Beneficially Owned: Each of Biotechnology and
Tetraven may be deemed to beneficially own 3,489,999
Ordinary Shares as of December 31, 1999.
Page 4 of 8 pages
<PAGE> 5
Biotechnology was the record owner of 2,908,327 Ordinary
Shares as of December 31, 1999. Tetraven was the record
owner of 581,672 Ordinary Shares as of December 31, 1999.
(The shares held of record by Biotechnology and Tetraven are
referred to collectively herein as the "Record Shares.") By
virtue of their relationship as affiliated corporations with
the same individuals as liquidators, each of Biotechnology
and Tetraven may be deemed to beneficially own all of the
Record Shares. Hence, each of Biotechnology and Tetraven may
be deemed to beneficially own 3,489,999 Ordinary Shares as
of December 31, 1999.
(b) Percent of Class: Biotechnology: 7.9%; Tetraven: 7.9%.
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
Biotechnology: 2,908,327 Ordinary Shares;
Tetraven: 581,672 Ordinary Shares.
(ii) shared power to vote or to direct the vote:
Biotechnology: 0 Ordinary Shares;
Tetraven: 0 Ordinary Shares.
(iii) sole power to dispose or to direct the disposition of:
Biotechnology: 2,908,327 Ordinary Shares;
Tetraven: 581,672 Ordinary Shares.
(iv) shared power to dispose or to direct the disposition
of:
Biotechnology: 0 Ordinary Shares;
Tetraven: 0 Ordinary Shares.
Each of Biotechnology and Tetraven expressly disclaims beneficial
ownership of any Ordinary Shares of Cantab Pharmaceuticals plc,
except, in the case of Biotechnology, for the 2,908,327 Ordinary
Shares that it holds of record and, in the case of Tetraven, for
the 581,672 Ordinary Shares that it holds of record.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY:
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
Not applicable
Page 5 of 8 pages
<PAGE> 6
ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
Not applicable.
ITEM 10. CERTIFICATIONS:
Not applicable. This statement on Schedule 13G is not filed pursuant
to Rule 13d-1(b) or Rule 13d-1(c).
Page 6 of 8 pages
<PAGE> 7
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief, each
of the undersigned certifies that the information set forth in this statement is
true, complete and correct.
Date: February 9, 2000
BIOTECHNOLOGY VENTURE FUND, S.A. (i.l.)
By: /s/ M. Rose DOCK
---------------------------------
Name: M. Rose DOCK
Title: LIQUIDATOR
By: /s/ Fernand HEIM
---------------------------------
Name: Fernand HEIM
Title: MANDATORY
TETRAVEN FUND S.A. (i.l.)
By: /s/ M. Rose DOCK
---------------------------------
Name: M. Rose DOCK
Title: LIQUIDATOR
By: /s/ Fernand HEIM
---------------------------------
Name: Fernand HEIM
Title: MANDATORY
Page 7 of 8 pages
<PAGE> 1
Exhibit 1
---------
AGREEMENT
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the
undersigned hereby agree that only one statement containing the information
required by Schedule 13G need be filed with respect to the ownership by each of
the undersigned of shares of stock of Cantab Pharmaceuticals plc.
This Agreement may be executed in any number of counterparts, each of which
shall be deemed an original.
EXECUTED this 9th day of February, 2000.
BIOTECHNOLOGY VENTURE FUND, S.A. (i.l.)
By: /s/ M. Rose DOCK
---------------------------------
Name: M. Rose DOCK
Title: LIQUIDATOR
By: /s/ Fernand HEIM
---------------------------------
Name: Fernand HEIM
Title: MANDATORY
TETRAVEN FUND S.A. (i.l.)
By: /s/ M. Rose DOCK
---------------------------------
Name: M. Rose DOCK
Title: LIQUIDATOR
By: /s/ Fernand HEIM
---------------------------------
Name: Fernand HEIM
Title: MANDATORY
Page 8 of 8 pages
